Continuous ambulatory peritoneal dialysis and bone  by Delmez, James A. et al.
Kidney International, Vol. 30 (1986), pp. 379—384
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Continuous ambulatory peritoneal dialysis and bone. We studied the
effects of continuous ambulatory peritoneal dialysis (CAPD) on the
histological manifestations of uremic hone disease. Twelve patients
underwent bone biopsy immediately prior to and after one year of such
treatment, Those with larger quantities of non-mineralized bone matrix
(osteoid) experienced a reduction in relative osteoid volume, mean
osteoid seam width, and total osteoid surface. Moreover, the use of
time—spaced kinetic markers of mineralization (tetracycline) enabled us
to demonstrate that CAPD usually decreased the amount of non-
mineralized bone matrix by shortening mineralization lag time (that is,
the interval from organic matrix deposition to its mineralization). The
changes in the histomorphology appeared to occur independently of
bone aluminum. These data indicate that CAPD generally enhances the
mineralizing capacity of individual osteoblasts and suggests that such
therapy is beneficial to the uremic skeleton.
The pathogenesis of renal osteodystrophy is among the best
understood of any generalized disorder of the skeleton. Fortu-
nately, this insight has been translated into successful therapeu-
tic programs resulting in a progressive reduction in the propor-
tion of hemodialysis patients who develop clinically significant
bone disease [13.
Continuous ambulatory peritoneal dialysis (CAPD) is a new
alternative to hemodialysis but has relatively unique metabolic
consequences which potentially influence the skeleton. In con-
trast to hemodialysis, for example, CAPD leads to removal of
immunoreactive parathyroid hormone (iPTH) [21. Both normal
[21 and low [3, 41 levels of 25-hydroxyvitamin D have been
noted in patients undergoing treatment with CAPD. Because
CAPD may impact on bone and has been reported to lead to
progressive renal osteodystrophy [5], we evaluated the effects
of twelve months of such treatment on the histology of the
uremic skeleton and found it beneficial.
Methods
Twelve patients were studied immediately prior to, and after
one year of CAPD. Their clinical characteristics are detailed in
Table 1. Four patients were maintained on hemodialysis for
between three and nine years, respectively, and the remaining
eight were treated medically before CAPD. Of these eight, three
patients were nephrotic. All had creatinine clearances less than
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Table 1. Clinical characterislics of the twe lye study patients
Prior
Pa- hemodi- Al (OH)
tient Sex Age alysis Renal disease Nephrotic g/day
I M 58 No Interstitial nephritis No 0.75
2 M 63 No Diabetes (type II) Yes 4.3
3 F 50 No Diabetes (type II) Yes 1.5
4 F 53 No Diabetes (type II) Yes 4.2
5 F 56 Yes Interstitial nephritis No 2.0
6 F 50 Yes Glomerulonephritis No 4.0
7 M 48 No Unknown No 1.5
S F 62 Yes Polycystic kidney
disease
No 4.0
9 F 36 No Interstitial nephritis No 3.0
10 M 68 No Hypertension No 1.4
11 M 52 Yes Crescentic glomer-
ulonephritis
No 9.0
12 F 52 No Unknown No 1.0
5 mI/mm/I .73 m2 at the start of CAPD and become oliguric
within three to four months of treatment, The dialysis regimen
was as previously described [21. Each patient usually ex-
changed three, 1.5% and one 4.25% dextrose dialysate solutions
(Dianeal, Baxter—Travenol Laboratories, Deerfield, Illinois,
USA) per day,
All subjects received oral calcium supplements in an attempt
to maintain circulating ionized calcium levels at, or slightly
above, the upper limits of normal (5.0 mg/dl). In most patients,
the amount of ingested elemental calcium was between 500 and
2,000 mg per day. Serum phosphorus concentrations were
controlled by aluminum hydroxide administration. No patient
was taking anticonvulsant drugs, vitamin D, or corticosteroids,
nor was there evidence of liver disease in any subjects.
Bioche,nical determinations
Eleven of the twelve patients had at least two determinations
of ionized calcium, phosphorus, immunoreactive parathyroid
hormone (iPTH), and alkaline phosphatase within two months
prior to initiation of CAPD. Thereafter, these parameters were
measured every four to six weeks and the mean values for the
twelve month period, calculated. Circulating ionized calcium
was measured using a flow—through membrane, electrode
(Orion Research, Cambridge, Massachusetts, USA) and phos-
phorus by routine laboratory methods adjusted for the
Technicon Auto Analyzer (Technicon Instruments Corpora-
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Table 2. Biochemical determinants5
Ionized calcium, Phosphorus, Alkaline phosphatase
mg/dl mg/dl lU/liter iPTH pJ Eq/mi
1 yr. 1 yr. 1 yr. 1 yr.
Patient Pre-CAPD CAPD Pre-CAPD CAPD Pre-CAPD CAPD Pre-CAPD CAPD
1 3.95 5.06 0.13 6.55 0.59 4.38 0.35 144 17 67 8 225 14 82 6
(1) (13) (4) (19) (7) (6) (6) (19)
2 4.34 0.1 4.85 0.2 3.71 0.82 5.02 0.24 180 12 71 12 61 5 28 S
(3) (11) (4) (12) (3) (4) (5) (11)
3 4.61 0.06 5.39 0.15 5.37 0.31 3.77 0.22 91 5 72 3 63 I 22 2
(2) (11) (9) (13) (7) (6) (3) (18)
4 4.44 0.07 4.63 0.21 3.89 0.51 4.70 0.69 262 10 134 5 111 14 59 11
(3) (6) (4) (8) (5) (5) (3) (9)5 5.0 0.11 5.11 0.10 5.06 0,36 5.22 0.37 49 2 67 5 114 14 127 8
(6) (11) (4) (10) (8) (6) (5) (21)6 5.24 0.21 4.95 0.15 4.82 0.6 4.96 0.15 170 30 173 20 320 24 520 88
(3) (11) (4) (11) (2) (5) (4) (11)
7 4.54 0.3 4.80 0.12 5.8 1 5.56 0.34 192 23 128 16 182 13 178 30
(2) (13) (2) (16) (3) (7) (5) (14)
8 5.42 0.09 5.20 0.25 5.39 0.26 4.58 0.29 79 9 118 II 279 78 394 72
(5) (7) (5) (7) (6) (3) (5) (9)
9 4.55 0.14 4.46 0.08 6.18 1.75 5.52 0.35 270 14 211 16 246 81 644 50
(2) (10) (4) (II) (3) (4) (2) (9)
10 4.83 0.29 5.11 0.12 4.85 1.63 4.96 0.40 76 5 54 3 97 61 39 6
(4) (11) (4) (13) (4) (4) (3) (9)
II 4.24 0.12 4.59 0.06 7.18 1.70 7.50 0.50 111 19 124 16 515 38 835 84
(3) (10) (3) (12) (4) (7) (3) (12)
12 5.14 0.63 4.74 0.13 5.24 0.90 5.05 0.47 64 5 55 6 65 10 40 7
(2) (8) (5) (8) (4) (6) (3) (9)
Normal
Range 4.5—5.0 2.5—4.5 35—100 <10
* Parentheses include number of determinations.
tion, Tarrytown, New York, USA). Parathyroid hormone levels
were determined by a radioimmunoassay which recognizes the
intact molecule and its carboxy-terminal portions [6]. The
majority of iPTH detected in the serum of patients on CAPD is
composed of the biologically inactive fragments of the terminal
part of the molecule [2].
Bone histomorphometry
Patients underwent a bone biopsy at the start of CAPD and
following one year of treatment. Each 5 mm transileal bone
specimen, obtained two days after two, three—day courses of
tetracycline (oxytetracycline, 1 g/day) separated by two weeks,
was fixed, embedded, and cut into non-decalcified sections as
previously described [7, 8]. The following histomorphometric
parameters were quantitated by use of an Osteoplan Image
Analyzer (Zeiss, Inc., New York, New York, USA) and the
parameters determined by tetracycline were quantitated by use
of an ocular grid:
(a) Total bone volume—fraction of marrow space occupied
by bone matrix;
(b) Relative osteoid volume (decimal fraction)—fraction of
trabecular bone matrix composed of osteoid (non-mineralized
bone matrix);
(c) Mean osteoid seam width (gm)
(d) Total osteoid surface (decimal fraction)—fraction of tra-
becular bone surface lined by osteoid seams;
(e) Osteoclast number/mm2—number of osteoclasts per mm2
of space containing trabecular bone and marrow;
(0 Fibrotic surface (decimal fraction)—fraction of trabecular
bone surface in apposition to fibrous tissue;
(g) Linear extent of mineralization—the decimal fraction of
trabecular bone surface capable of assuming a tetracycline lab
el,
(h) Cellular rate of mineralization (.tm/day)—mean distance
between the midpoints of double tetracycline labels divided by
17 (number of days between the midpoint of the two courses of
tetracycline);
(i) Decimal fraction of osteoid seams exhibiting a tetracycline
label;
(j) Mineralization lag time (days)—this is a calculated value
derived by dividing the product of the decimal fraction of
tetracycline labeled seams and the mean osteoid seam width by
the cellular rate of mineralization [8].
The "static" (non-tetracycline based) parameters were com-
pared to iliac crest bone processed in our laboratory from
twelve, similarly aged white females (mean age 48.8 18.5 (SD)
years who died suddenly and the dynamic measurements (tet-
racycline based), compared to those of normal women, pub-
lished by Melsen and Mosekilde [9, 10].
The histological stain for aluminum deposition in bone was
performed according to the method of Maloney et al [11].
Statistics
Statistical analyses were performed using the Student's (-test
and linear regression by least squares. All results are reported
as the mean SEM.
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Table 3. Static analysis of bone histology
Total bone volume Relative osteoid volume (decimal
(TBV) fraction) Mean osteoid seam width (sm)
1 yr. 1 yr. 1 yr.
Patient Pre-CAPD CAPD Pre-CAPD CAPD Pre-CAPD CAPD
1 20.39 19.89 0.20 0.08 15.9 10.4
2 24.36 23.13 0.22 0.10 14.9 8.5
3 18.39 28.12 0.06 0.04 8.7 6.3
4 13.72 19.15 0.35 0.07 18.8 12.0
5 10.75 12.49 0.25 0.06 9.9 9.1
6 12.65 12.64 0.11 0.10 15.4 11.5
7 10.46 10.51 0.17 0.25 14.3 13.8
8 16.07 20.74 0.13 0.06 8.5 10.5
9 40.08 45.58 0.33 0.08 24.6 13.9
10 16.66 20.40 0.03 0.04 6.9 7.1
11 16.78 14.70 0.07 0.09 7.3 8.7
12 17.77 22.57 0.13 0.17 11.0 13.2
X SCM 18.7 7.96 20.82 9.31 0.17 0.03 0.09 0.02 13.0 1.5 10.4 0.9
Normal
Range 5.1—38.7 0—0.06 0—23
Table 3. Continued
Total osteoid surface (decimal Fibrotic surface
fraction) Osteoclasts/m,n2 (decimal fraction)
Patient 1 yr. 1 yr. 1 yr.
Pre-CAPD CAPD Pre-CAPD CAPD pre-CAPD CAPD
1 0.55 0.29 3.38 0.80 0.342 0.004
2 0.62 0.55 0.97 0.12 0.093 0
3 0.27 0.26 0.03 0.00 0.006 0
4 0.83 0.36 0.00 0.60 0.008 0.012
5 0.62 0.21 0.31 0.37 0.029 0.020
6 0.37 0.41 1.16 1.24 0.341 0.440
7 0.36 0.65 1.65 0.78 0.232 0.280
8 0,69 0.37 0.79 1.18 0.026 0.015
9 0.72 0.48 4.31 2.16 0.352 0.352
10 0.23 0.38 0.00 0.00 0.003 0.000
11 0.56 0.77 0.15 0.19 0.284 0.131
12 0.81 0.76 0.11 0.49 0.003 0.032
X it SCM 0.55 0.66 .46 0.05 1.07 0.41 0.66 0.18 0.143 0.044 0.107 0.046
Normal
Range 0—0.40 0—0.35 0
Results Bone histology
Biochemical parameters
The levels of ionized calcium, phosphorus, alkaline phospha-
tase, and iPTH prior to and during the twelve—month treatment
period on CAPD are shown on Table 2. There was no overall
change in the ionized calcium (pre 4.69 0,13 mgldl, during
4.91 0.08 mg/dl) or phosphorus (pre 5.34 0.29 mg/dl, during
5.10 0.26 mg!dl) levels during the study periods. However,
there was a significant fall in the alkaline phosphatase concen-
tration while on CAPD (pre 140 21, during 106 15, P <
0.05). As previously reported [21, the effects of CAPD on iPTFI
levels are variable. In five patients there was an approximate
fifty percent or more drop in iPTH concentrations while on
CAPD, whereas there was a greater than fifty percent rise in
three. The remaining four patients did not demonstrate such
marked changes.
The initial biopsies of all twelve patients had some features of
renal osteodystrophy (Table 3). Ten had an abundance of
osteoid if expressed as a proportion of bone matrix (relative
osteoid volume) or eight if defined in terms of percentage of
bone surface covered by unmineralized matrix (total osteoid
surface). The number of osteoclasts was increased in six and all
had peritrabecular marrow fibrosis, a distinctly abnormal find-
ing which in renal failure reflects enhanced PTH effect on bone.
Four had histological evidence of bone aluminum accumulation
(Table 4), two of whom (No. 5 and No. 6) had been maintained
on hemodialysis. Analysis of the kinetic histomorphometric
parameters indicate that nine of twelve patients had a decreased
fraction of osteoid seams capable of assuming a tetracycline
label (Table 5). The general failure of uremic osteohiasts to
mineralize bone is more globally expressed in terms of the
mineralization lag time which was markedly prolonged in eight
of twelve patients.
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Table 4. Aluminum stains of the bone biopsies
% Total surface picking up
aluminum (decimal frac- % Aluminum surface!
Patient
tion) %TOS (decimal fraction)
Pre-CAPD I yr. CAPD Pre-CAPD 1 yr. CAPD
1 000 0.00 0.00 0.00
2 0.00 0.00 0.00 0.00
3 0.00 0.00 0.00 0.00
4 0.19 0.32 0.23 0.89
5 0.35 0.24 0.57 1.15
6 0.39 0.11 1.07 0.26
7 0.00 0.00 0.00 0.00
8 0.29 0.00 0.41 0.00
9 0.00 0.00 0.00 0.00
10 0.00 0.15 0.00 0.40
II 0.00 0.00 0.00 0.00
12 0.00 0.00 0.00 0.00
X SEM 0.10 0.05 0.07 0.03 0.19 0.10 0.23 0.11
The static (non-tetracycline—based) features of the biopsies
improved in most patients after one year of CAPD. In those
eight patients with an initial increase in total osteoid surface,
seven experienced a decline (P < 0.05) (Fig. 1). Although not
statistically significant, there was also an overall decrease in the
relative osteoid volume (pre 0.17 0.03, 1 year 0.09 0.02) and
mean osteoid seam width (pre 13.0 1.5 m, 1 year 10.4 0.9
.rm). The improvement was most evident in those patients
demonstrating the greatest accumulation of osteoid on the
initial biopsy. The number of osteoclasts per mm2 decreased
from 1.07 0.41 to 0.66 0.66, and the fibrotic surface fell
from 0.143 0.044 to 0.107 0.046. While changes in these
indices of osteitis fibrosa (OF) did not reach significance, this
may reflect the variable effects of CAPD on iPTH levels. In
most patients the changes of OF mirrored those changes in
serum iPTH levels. Overall, there was a close correlation with
iPTH levels and fibrotic surface (r 0.585, P = 0.003).
Eight patients had no histological evidence of aluminum
accumulation at the start of CAPD, whereas in four, the cation
was present on initial biopsy. Despite the continued ingestion of
aluminum—containing gels, only one of the eight patients with-
out aluminum on the initial biopsy developed subsequent evi-
dence of its accumulation in bone. Of the four who initially had
aluminum, two developed increased and two decreased
amounts of aluminum after one year of CAPD (Table 4).
CAPD had dramatic effects on tetracycline—based measure-
ments (Table 5). Following one year of therapy all hut one
biopsy contained double tetracycline labels, and the mean
cellular rate of mineralization became almost twice the normal,
a phenomenon we have previously noted in hemodialyzed
patients [12]. Most strikingly, the mineralization lag time dimin-
ished in seven of eight patients in whom it was initially
prolonged (P < 0.025) (Fig. 2).
These data suggest that one year of CAPO had, in most
patients, a beneficial effect but offers no information regarding
the specificity of this treatment. We, therefore, retrospectively
studied the bone biopsies of nine patients who had been
maintained on hemodialysis for 12.6 6.1 (SD) months. While
these biopsies were essentially no different than those obtained
from the pre-CAPD group, they generally contained more
osteoid than encountered following one year of peritoneal
dialysis. This difference in the effects of the two forms of
dialysis is most dramatically illustrated by the approximate 50%
greater extent of total osteoid surface in the hemodialysis
relative to CAPD patients (P < 0.005).
Discussion
Our data indicate that one year of CAPD is not detrimental,
and in fact, appears to be beneficial, to bone. The abundant
quantity of non-mineralized matrix, a hallmark of renal osteo-
dystrophy [I] is particularly effected. This change is most
dramatically expressed in terms of the total osteoid surface
which declined in these patients in whom it was initially
increased.
The quantity of osteoid is a reflection of the relative rates of
its synthesis and mineralization, and a fall in the amount of
unmineralized matrix reflects either: I) enhancement of its
mineralization, or 2) a decreased rate of osteoid production [6].
Distinction between these two possibilities can only be
achieved by the use of time—spaced courses of tetracycline as
morphological markers of the rates of mineralization [61. Using
this approach, we measured two basic parameters of bone
mineralization; namely: 1) the cellular rate of mineralization
which reflects the rate of calcification by the average osteo-
blasts, and 2) the percentage of tetracycline—labeled osteoid,
which is a measurement of the proportion of ostcoblasts which
have been recruited into the mineralization process. Taken with
the mean osteoid seam width, these tetracycline—based param-
0.9
0.8
07
0.6
0.5
0.4
0.3
0.2
Pre 1 yesr
CAPD
Total osteold surface
Fig. 1. The effect of GAPD on total osteoid surface. Of the eight
patients with large amounts of ostoid, seven demonstrated improve-
ment after 12 months on CAPD (P < 0.05).
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Table 5. Kinetic parameters of bone biopsies
Linear extent of mineraliza-
tion (decimal fraction)
Cellular rate of mineraliza-
tion (gm/day)
Tetracycline labeled osteoid
seams (decimal fraction)
Mineralization lag time
(days)
lyr. lyr.
Patient Pre-CAPD 1 yr. CAPD Pre-CAPD CAPD Pre-CAPD CAPD Pre-CAPD 1 yr. CAPD
1 0.36 0.08 0.89 0.85 0.66 0.29 27.1 42.4
2 0.05 0 0.74 0 0.08 0 251.7 337.8
3 0 0.10 0 0.92 0 0.39 345.8 17.6
4 38 0.14 1.03 1.00 0.45 0.40 40.5 30.1
5 0.02 0.03 1.04 1.82 0.03 0.13 318.3 38.6
6 0 0.35 0 1.40 0 0.87 612.0 9.4
7 0.04 0.22 1.17 1.41 0.11 0.33 110.9 29.7
8 0.07 0.16 1.30 1.18 0.10 0.44 65.5 20.2
9 0.64 0.48 1.26 1.40 0.88 1.00 22.2 9.9
10 0.04 0.07 0 0.95 0.15 0.18 62.2 41.5
Ii 0.12 0.20 1.02 0.88 0.21 0.27 34.2 36.4
12 0.06 0.06 0 0.98 0.07 0.08 212.4 168.0
X SaM 0.15 0.06 0.16 0.04 0.70 0.16 1.07 0.13 0.23 0.08 0.37 0.09 175.2 52.0 65.0 27.6
Normal
Range 0.01—0.26 0.41—0.89 0.42—1.00 8—52
200
150
100
Mineralization lag time
Fig. 2. The effect of CAP!) on mineralization lag time. Of the eight
patients with an initial prolonged lag time, seven improved after 12
months on CAPD (P < 0.025).
eters permitted us to calculate the mineralization lag time [10].
This value reflects both individual osteoblast activity (cellular
rate of mineralization) and the capacity to recruit osteoblasts
into the mineralization process (tetracycline—labeled osteoid
seams). A decline in the mineralization lag time in seven of eight
patients in whom it was initially prolonged, indicates that in
general, CAPD has a beneficial effect upon calcification of
uremic bone, In contrast, however, patient No. 2 who experi-
enced a dramatic reduction of all osteoid—hased measurements,
demonstrated a worsening of the kinetics of hone calcification.
This combination of diminution of both osteoid volume and
mineralization rate is best explained by an attendant and
profound decline in organic matrix synthesis. Despite the fact
that the quantity of unmineralized hone matrix diminished
under these circumstances, it is unclear if the effect was
beneficial, For example, we [13] and others [14, Donald J.
Sherrard, personal communicationi have encountered patients
with a variety of potentially osteomalacic disorders, such as
renal failure and liver dysfunction, who, in association with
severely disabling bone disease, have a paucity of osteoid due
to reduced organic matrix synthesis.
Our contention that CAPD may be beneficial to the uremic
skeleton is supported by the recent observations of Gokal et al
from Newcastle—upon—Tyne [3], hut there are important differ-
ences between the two studies. For example, 60% of the
English patients on CAPD longer than nine months developed
subnormal circulating levels of 25-hydroxyvitamin D, whereas
we have previously shown normal concentrations [2]. This
distinction may relate to the well established differences in the
manifestations of renal osteodystrophy in England and the
United States [15, 16]. Moreover, four of the seven of Gokal's
sequentially biopsied patients, who had been maintained on
CAPD for at least one year, received supplemental 1-aipha-hy-
droxyvitamin D3. Because this drug is beneficial to the uremic
skeleton [17], it is impossible to distinguish its effect from that
of CAPD per Se. Finally, and most importantly, the use of
time—spaced markers of mineralization in the present study has
permitted us to ferret out the kinetic changes leading to reduc-
lion of osteoid under the influence of this form of dialysis. More
recently, Zuechelli et al [18] compared the histological changes
of 17 patients treated with CAPD to 19 receiving maintenance
hemodialysis. No changes in the % osteoid volume or % osteoid
surface was noted in the group treated with CAPD. However,
as opposed to the hemodialysis group, a significant decline in
the percent absolute cancellous bone volume was noted, an
observation we have been unable to confirm.
The precise factors responsible for the reduction of osteoid
by CAPD are, however, enigmatic. For example, there is little
650
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evidence that PTH per se is directly involved in the mineraliza-
tion process [12]. This hormone does, however, lead to humoral
events, such as altered alkaline phosphatase activity, which are
more closely aligned with calcification [19]. In any event,
CAPD treatment for one year appears to be associated with a
general reduction in the thickness of osteoid seams, which in
most patients is due to healing osteomalacia. These beneficial
effects are not due to changes in bone aluminum.
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